These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 29558951)
21. Switchable CAR T cell strategy against osteosarcoma. Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034 [TBL] [Abstract][Full Text] [Related]
22. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286 [TBL] [Abstract][Full Text] [Related]
23. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. Zhang E; Xu H J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484 [TBL] [Abstract][Full Text] [Related]
24. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Wang W; Ma Y; Li J; Shi HS; Wang LQ; Guo FC; Zhang J; Li D; Mo BH; Wen F; Liu T; Liu YT; Wang YS; Wei YQ Gene Ther; 2013 Oct; 20(10):970-8. PubMed ID: 23636245 [TBL] [Abstract][Full Text] [Related]
25. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
26. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319 [TBL] [Abstract][Full Text] [Related]
27. Effective Targeting of TAG72 Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ Front Immunol; 2018; 9():2268. PubMed ID: 30510550 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739 [TBL] [Abstract][Full Text] [Related]
29. Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. Casucci M; Falcone L; Camisa B; Norelli M; Porcellini S; Stornaiuolo A; Ciceri F; Traversari C; Bordignon C; Bonini C; Bondanza A Front Immunol; 2018; 9():507. PubMed ID: 29619024 [TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
31. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926 [TBL] [Abstract][Full Text] [Related]
33. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer. Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663 [TBL] [Abstract][Full Text] [Related]
34. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562 [TBL] [Abstract][Full Text] [Related]
35. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636 [TBL] [Abstract][Full Text] [Related]
36. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Ma Q; Gomes EM; Lo AS; Junghans RP Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378 [TBL] [Abstract][Full Text] [Related]
37. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Zhao L; Liu Y; Zhao F; Jin Y; Feng J; Geng R; Sun J; Kang L; Yu L; Wei Y Mol Ther Oncolytics; 2020 Mar; 16():262-271. PubMed ID: 32181327 [TBL] [Abstract][Full Text] [Related]
39. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy. Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655 [TBL] [Abstract][Full Text] [Related]
40. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]